Dual Therapy to Elevate Gonorrhea Therapeutics Sales through 2021: Fact.MR

Surging cases of sexually transmitted disease is spurring researchers to verify and reintroduce new innovations for the treatment

Award winning market research company Fact.MR has conducted a study on the global gonorrhea therapeutics market. Fact.MR study forecasts the market to register a moderate growth nearly at a CAGR of 4% through 2029. The study further projects that gonorrhea therapeutics sales are expected to prevail owing to the bulk investments by manufacturers.

Growing number of clinical trials and investments in healthcare sector is aiding the growth of gonorrhea therapeutics. According to the study, dual therapy will be the primary choice of treatment and is expected to account for 90% of market shares. Hence, advancing the sales of gonorrhea therapeutics.

For instance, according to the Centre for Disease Control and Prevention, the recommended dosage for the gonorrhea treatment is Azithromycin combined with 500 mg intramuscular dose of ceftriaxone.

“The Fact.MR study projects that dual therapy is the most recommended treatment for people with symptomatic and asymptomatic gonorrhea, enabling aggrandizing sales for macrolide antibiotics,” says the Fact.MR analyst.

Request a report sample to gain comprehensive insights at https://www.factmr.com/connectus/sample?flag=S&rep_id=3761

Key Takeaways

  • Dual therapy remains the preferred therapy type
  • US gonorrhea therapeutic sales will be steady in 2021
  • East Asian countries likely to witness strong sales
  • Third-generation cephalosporin sales for gonorrhea treatment to rise in upcoming years
  • Azithromycin will capture nearly half of market share

Prominent Drivers

  • Manufacturers are finding increased opportunities in development of new diagnostic tests, such as nucleic acid amplification tests (NAATs)
  • Rising government and private organizations initiatives through campaigns, coupled with low cost of gonorrhea therapeutic to be a key driver
  • Increasing cases of antimicrobial resistance (AMR) is enabling rise in R&D activities, aiding the sales of gonorrhea therapeutics

Key Restraints

  • Stringent regulations and social stigma associated with people regarding the visits to the STD clinics is hampering the growth
  • Insufficient research and lack of sufficient investment to hamper the growth of the gonorrhea therapeutics

Discover more about the gonorrhea therapeutics market with 202 figures, 52 data tables and the table of contents. You will also find detailed market segmentation on https://www.factmr.com/report/3761/gonorrhea therapeutics-market

Competitive Landscape

Key Gonorrhea therapeutics market players profiled by Fact.MR include Teva Pharmaceutical Industries Ltd., Bayer AG, Mylan N.V., Merck & Co., Allergan PLC., Hoffmann-La Roche Ltd., Sanofi S.A., Baxter International Inc., GlaxoSmithKline PLC., Pfizer Inc., and Novartis AG among others. According to the Fact.MR analysis, the market is expected to be fairly fragmented and the key players are focusing on strategies such as product innovation for future expansion.

For instance, in 2020, Intravacc partnered with Therapyx to develop and optimize its first prophylactic gonorrhea vaccine. For this, the latter received a Phase IIB grant of $2.8 million in U.S. for its capabilities and infrastructure for the optimization of vaccines and vaccine technologies.

Likewise, in 2019, GlaxoSmithKline partnered with U.S. governments Biomedical Advanced Research & Development and started a phase III clinical program for a potential first-in-class antibiotic, gepotidacin. The organization developed the study to compare gepotidacin to ceftriaxone plus azithromycin, a guideline recommended for dual therapy approach, in approximately 600 patients diagnosed with gonorrhea.

More Insights on the Gonorrhea Therapeutics Market

In its latest report, Fact.MR offers unbiased analysis of the global Gonorrhea therapeutics market. In order to understand the global market potential, its growth, and scope, the market is segmented on the basis of drug type (macrolide antibiotics, third-generation cephalosporin, tetracycline antibiotics, fluoroquinolones antibiotocs, aminoglycoside and aminocyclitol), therapy type (mono therapy and dual therapy), route of administration (oral and intra muscular), distribution channel (institutional sales and retail sales), and regions (North America, Latin America, Europe, South Asia, East Asia, Oceania, and Middle East and Africa)

Request more information about Report Methodology


Explore Fact.MR’s Coverage on the Healthcare Domain

Vaginal Rejuvenation Market: A recent study by Fact.MR on the vaginal rejuvenation market offers an unbiased analysis on the opportunities and challenges for the forecast period. The study analyzes crucial trends that are currently determining market growth. This report explicates on vital dynamics, such as the drivers, restraints, and opportunities for key market players along with key stakeholders and emerging players.

Bacterial Antigens Market: A detailed assessment of bacterial antigens value chain analysis, business execution, and supply chain analysis across regional markets has been covered in the report. A list of prominent companies operating in the bacterial antigens market along with their product portfolios enhances the reliability of this comprehensive research study.

Perianal Infection Treatment Market: Fact.MR has published an exhaustive market study on the global market for perianal infection treatment. A comprehensive estimate on perianal infection treatment market has been provided through an optimistic scenario as well as a conservative scenario, taking into account the sales of perianal infection treatment market during the forecast period.

About Fact.MR

Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. We have offices in US and Dublin, whereas our global headquarter is in Dubai. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Reach out to us with your goals, and we’ll be an able research partner.

Sudip Saha
US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
E: sales@factmr.com
Corporate Headquarter:
Unit No: AU-01-H Gold Tower (AU),
Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers,
Dubai, United Arab Emirates
Source: Fact.MR

Back to news